Harbour BioMed announced that it has completed a Series B round financing of $85 million to accelerate the growth of its innovative therapeutic pipeline, including both clinical and discovery stage programs.
Harbour BioMed was established in December 2016 around a Series A round of $50 million and the acquisition of the Netherlands-based fully human transgenic antibody technology company, Harbour Antibodies BV and its subsidiaries. The company has integrated the Harbour Mice technologies into its newly built antibody technology and discovery biology, preclinical and clinical development operations, entered into multiple license and collaboration agreements for its Harbour Mice, and established an innovative therapeutic pipeline based on internal discovery and in licensing activities.
Harbour’s development programs include:
- An anti-FcRn based antibody against multiple autoimmune diseases, including myasthenia gravis and neuromyelitis optica, and a biologic against inflammatory dry-eye disease, among other potential indications. Harbour, which in-licensed these assets in 2017. Harbour recently filed two INDs for three different indications in China to conduct clinical trials with these assets.
- A CD3-based bi-specific antibody therapy against Her-2 overexpressed cancer in clinical development, acquired in August 2018, which Harbour is developing for the Greater China market.
- A clinical stage, anti-PD-L1 antibody for the treatment of multiple solid tumors and hematological cancers, acquired in August 2018.
Harbour BioMed is a global biopharmaceutical company discovering and developing innovative therapeutics for oncology and immunological diseases. Discovery and development programs are built around its two patented transgenic mouse platforms for therapeutic antibody discovery. Harbour BioMed also licenses the platforms to companies and academic institutions through its Harbour Antibodies subsidiary. The company has operation and an R&D site in Shanghai, China, business operations and innovation center including research laboratory in Boston, USA, and an antibody platform innovation center in Rotterdam, The Netherlands.